| 1994 |
PRL-1 (PTP4A1) encodes a 20-kDa protein tyrosine phosphatase capable of dephosphorylating phosphotyrosine substrates; mutation of the active-site cysteine abolishes phosphatase activity. PRL-1 is located primarily in the cell nucleus, and stable overexpression causes altered cellular growth, morphology, and a transformed phenotype. |
Active-site mutagenesis, in vitro phosphatase assay, immunofluorescence, stable transfection with phenotypic readout |
Molecular and cellular biology |
High |
8196618
|
| 2000 |
PRL-1, -2, and -3 are prenylated at their C-terminal CAAX motif; prenylation is required for their primary association with the plasma membrane and early endosomal compartment. Inhibition of farnesyltransferase (FTI-277) or deletion of the prenylation signal causes nuclear relocalization of PRL-1. |
Farnesyltransferase inhibitor treatment, prenylation-deficient mutants, electron microscope immunogold labeling, brefeldin A/wortmannin treatment, subcellular fractionation |
The Journal of biological chemistry |
High |
10747914
|
| 2002 |
PRL-1 exhibits cell cycle-dependent subcellular localization: in non-mitotic HeLa cells it localizes to the endoplasmic reticulum in a farnesylation-dependent manner; in mitotic cells it relocalizes to centrosomes and the spindle apparatus in a farnesylation-independent manner. Expression of a catalytic-domain mutant delays mitotic progression, and a farnesylation-site mutant causes chromosomal bridges and lagging chromosomes without affecting spindle checkpoint function. |
Immunofluorescence of endogenous protein, conditional expression of catalytic/farnesylation mutants, cell cycle analysis |
The Journal of biological chemistry |
High |
12235145
|
| 2003 |
PRL-1 (and PRL-3) promote cell motility, invasive activity, and metastasis in vivo; catalytically inactive PRL-3 mutant shows significantly reduced migration-promoting activity, indicating the phosphatase activity is required. PRL-1/3-expressing CHO cells form metastatic tumors in mice. |
Stable CHO cell expression, catalytically inactive mutant, migration/invasion assays, in vivo mouse metastasis model |
Cancer research |
High |
12782572
|
| 2005 |
Crystal structure of PRL-1 reveals it is a dual-specificity phosphatase most similar to Cdc14; it forms a trimer in the crystalline state burying ~1140 Ų per dimer interface. Trimerization creates a membrane-binding surface combining C-terminal basic residues with the prenylation group. Native PRL-1 crystallizes in an oxidized form with a disulfide between active-site Cys104 and neighboring Cys49, blocking substrate binding and catalysis; biochemical studies in solution and in cells support a regulatory role for this intramolecular disulfide in response to H2O2. |
X-ray crystallography (native and C104S mutant), biochemical kinetic analyses, oxidation studies in cell lysates |
Biochemistry |
High |
16142898
|
| 2005 |
Crystal structure of human PRL-1 at 2.7 Å confirms trimeric assembly in the crystal; the trimer is also detected in the membrane fraction of cells, supporting biological relevance of oligomerization for PRL-1 activity regulation. |
X-ray crystallography, subcellular fractionation (membrane fraction immunoblot) |
Journal of molecular biology |
High |
15571731
|
| 2001 |
PRL-1 physically interacts with the bZIP transcription factor ATF-7 via its phosphatase domain (interacting with ATF-7's bZIP region); PRL-1 can dephosphorylate ATF-7 in vitro, identifying ATF-7 as a substrate. |
Yeast two-hybrid, domain mapping, in vitro dephosphorylation assay |
The Journal of biological chemistry |
Medium |
11278933
|
| 2007 |
PRL-1 promotes cell migration and invasion by activating Src kinase (increased Tyr416 phosphorylation), leading to phosphorylation of focal adhesion kinase (FAK) and p130Cas, and ERK1/2 activation. MMP2 and MMP9 levels are increased downstream of PRL-1 through AP1 and Sp1 transcription factors; MMP2/MMP9 knockdown or inhibition blocks PRL-1-mediated migration. Src and ERK1/2 activities are required for PRL-1-induced MMP upregulation. |
Stable overexpression, siRNA knockdown, pharmacological inhibition, western blotting for pathway components, migration/invasion assays |
Biochemistry |
Medium |
19199380
|
| 2007 |
Knockdown of PRL-1 in human A549 lung cancer cells decreases c-Src and p130Cas expression and reduces Rac1 and Cdc42 activation, implicating PRL-1 in regulating cell adhesion and migration through these GTPases. |
Stable shRNA knockdown, western blot, GTPase activation assays, immunofluorescence |
Cancer research |
Medium |
17234774
|
| 2007 |
PRL-1 phosphatase activity, trimerization, and the C-terminal polybasic region are each individually required for PRL-1-mediated cell proliferation and migration. The polybasic region mediates specific phosphoinositide recognition; both polybasic residues and the adjacent prenylation motif are required for proper subcellular localization and full biological activity. |
Cell-based overexpression/knockdown, trimer-disrupting and polybasic-region mutants, phosphoinositide-binding assays, migration/proliferation assays |
The Journal of biological chemistry |
High |
17656357
|
| 2008 |
PRL-1 overexpression reduces p53 protein levels via two independent pathways: induction of PIRH2 transcription and induction of MDM2 phosphorylation through Akt signaling, both leading to p53 ubiquitination and proteasomal degradation. Conversely, siRNA ablation of PRL-1 increases p53 levels. PRL-1 transcription is regulated by p53 via a response element in its first intron, forming a negative feedback loop. |
Overexpression, siRNA knockdown, ubiquitination assays, Akt inhibition, luciferase reporter (p53-RE) |
Oncogene |
Medium |
18997816
|
| 2011 |
PRL-1 directly binds the SH3 domain of p115 RhoGAP in vitro and in cells via a non-canonical interaction in which the PxxP ligand-binding site of the p115 RhoGAP SH3 domain occupies a groove in PRL-1. This prevents the canonical SH3–MEKK1 interaction, resulting in ERK1/2 activation; PRL-1 binding also inhibits the RhoGAP catalytic activity, leading to RhoA activation. |
In vitro pulldown, Co-IP in cells, X-ray structure of PRL-1·peptide complex, kinase/GAP activity assays |
The Journal of biological chemistry |
High |
22009749
|
| 2016 |
Crystal structure of PRL-1 in complex with the Bateman module (CBS domains) of the magnesium transporter CNNM2 reveals a heterotetrameric assembly: a disc-like CNNM2BAT homodimer bound to two independent PRL-1 molecules at opposite tips. The interaction occurs via the catalytic domain of PRL-1, with Asp-558 in the CBS2 loop of CNNM2 critical for the association. PRL-1 binding to CNNM2 is proposed to increase intracellular Mg²⁺ and promote oncogenic transformation. |
X-ray crystallography, mutagenesis of key interface residues |
The Journal of biological chemistry |
High |
27899452
|
| 2016 |
PRL1 (PTP4A1) knockout mice are fertile and show normal spermatogenesis, but combined PRL1/PRL2 reduction causes testicular atrophy and complete infertility. Mechanistically, total PRL1+PRL2 levels are negatively correlated with PTEN protein in the testis; loss of both PRLs elevates PTEN, attenuates Akt activation, and increases germ cell apoptosis. |
Knockout mice, western blot for PTEN/Akt, genetic epistasis (compound knockouts), histology |
Scientific reports |
Medium |
27666520
|
| 2017 |
PTP4A1 promotes TGFβ signaling in dermal fibroblasts and bleomycin-induced fibrosis in vivo by enhancing ERK activity, which stimulates SMAD3 expression and nuclear translocation. Upstream of ERK, PTP4A1 directly interacts with SRC and inhibits SRC basal activation independently of its phosphatase activity. PTP4A2 minimally interacts with SRC and does not activate this pathway. |
Primary fibroblast overexpression/KD, Co-IP for PTP4A1–SRC interaction, in vivo bleomycin model, western blot for ERK/SMAD3, phosphatase-dead mutant |
Nature communications |
High |
29057934
|
| 2007 |
Oxidative stress reversibly inhibits PRL-1 phosphatase activity through formation of an intramolecular disulfide bridge between Cys104 (active site) and Cys49, observed in vitro, in cultured cone cells, and in isolated retinas exposed to H2O2. |
In vitro phosphatase assay with H2O2 treatment, cell culture and isolated retina experiments, cycloheximide chase |
Biochimica et biophysica acta |
Medium |
17673310
|
| 2019 |
In Drosophila, the PRL-1 ortholog is a membrane-anchored phosphatase that promotes presynapse formation on a specific axon collateral of mechanosensory neurons; loss of Prl-1 reduces CNS presynapses and causes locomotor defects. Prl-1 modulates insulin receptor (InR) signaling within a single contralateral axon compartment. Branch-specific localization and function of Prl-1 depend on untranslated regions (UTRs) of the prl-1 mRNA. |
Genetic loss-of-function in Drosophila, transgenic overexpression, neuron-specific imaging, InR epistasis, UTR deletion constructs |
Science |
High |
31048465
|
| 2022 |
PTP4A1 dephosphorylates cytohesin-2 at Tyr381 in Schwann cells, reducing its activity. The adaptor SH2B1 maintains phosphorylation at Tyr381 by interacting with cytohesin-2. Schwann cell-specific knockdown of PTP4A1 increases cytohesin-2 phosphorylation and myelin thickness; loss of SH2B1 reduces phosphorylation and myelin thickness. Knockin of a non-phosphorylatable Y381F cytohesin-2 reduces Arf6 activity and myelin thickness. |
Knockin mice (Y381F), Schwann cell-specific conditional knockdown, Co-IP, Arf6 activity assay, sciatic nerve histology |
Science signaling |
High |
35077201
|
| 2023 |
PRL-1/2 (PTP4A1/PTP4A2) control intracellular magnesium levels by modulating TRPM7 channel activity through CNNM transporters. CNNM inhibits TRPM7; PRL-2 overexpression counteracts ARL15-mediated CNNM3/TRPM7 complex formation, enhancing TRPM7 function and intracellular Mg²⁺. PRL-1/2 knockdown restores CNNM3–TRPM7 interaction; co-targeting TRPM7 and PRL-1/2 alters mitochondrial function and sensitizes cells to metabolic stress. |
Genetically encoded Mg²⁺ reporter, Co-IP for protein complex formation, TRPM7 activity assays, siRNA knockdown, mitochondrial function assays |
PNAS |
High |
36972446
|
| 2023 |
PTP4A1 dephosphorylates the transcription factor USF1 at Ser309, increasing USF1 transcriptional activity. This induces expression of A20 (TNFAIP3), which inhibits NF-κB activity, reducing expression of cell adhesion molecules (CAMs) in endothelial cells. Ptp4a1 knockout mice show exacerbated IL-1β-induced CAM expression and atherosclerosis on a high-fat diet. |
shRNA knockdown and overexpression, luciferase reporter assay, ChIP assay, site-specific phosphorylation analysis, Ptp4a1 KO and transgenic mice, in vivo atherosclerosis model |
Cardiovascular research |
High |
36534975
|
| 2023 |
PTP4A1 deficiency worsens hepatosteatosis and glucose homeostasis in high-fat diet mice. PTP4A1 activates the CREBH/FGF21 transcriptional axis to prevent lipid accumulation; liver-specific overexpression of PTP4A1 or systemic FGF21 restores metabolic phenotypes in Ptp4a1-null mice. |
Ptp4a1 knockout mice, AAV-mediated liver-specific overexpression, adenoviral FGF21 overexpression, hyperinsulinemic-euglycemic clamp, luciferase reporter (CREBH), immunoprecipitation, primary hepatocytes |
Theranostics |
Medium |
36793871
|
| 2024 |
PRL-1 (and PRL-3) function as lipid phosphatases that convert PI(3,4)P2 and PI(3,5)P2 to PI(3)P on cellular membranes; this lipid phosphatase activity promotes membrane ruffles, membrane blebbing, and macropinocytosis, facilitating nutrient uptake, cell migration, and invasion. |
Cellular assays (membrane ruffle/bleb imaging), biochemical phosphoinositide substrate assays, protein interactome profiling, functional macropinocytosis assays |
Theranostics |
Medium |
38948056
|
| 2023 |
PTP4A1 binds to pyruvate kinase isoenzyme M2 (PKM2) to promote its expression and to aconitase 2 (ACO2) to enhance its degradation, thereby reprogramming mitochondrial metabolism to enhance invasive capacity of oral squamous cell carcinoma cells. |
Co-immunoprecipitation, western blot for PKM2/ACO2, overexpression/knockdown, in vitro invasion assays, in vivo tumor model |
Cell death discovery |
Medium |
37773151
|
| 2025 |
Crystal structure of the phosphocysteine intermediate of PRL1 (PTP4A1) determined using a C49S/D72A double mutant that stabilizes the phosphocysteine. The structure shows that phosphocysteine sterically interferes with CNNM binding. An aspartic acid (D72) mutation increases the initial rate of catalysis for PRL1/2/3, opposite to the effect seen in classical PTPs (PTP1B, PTPN12), highlighting mechanistic differences in the hydrolysis step. |
X-ray crystallography of phosphocysteine intermediate, mutagenesis, in vitro enzyme assays for all three PRL paralogs and classical PTPs |
The Journal of biological chemistry |
High |
40398601
|
| 2025 |
PTP4A1 physically interacts with PTEN (confirmed by Co-IP and immunofluorescence co-localization), suppresses PTEN phosphorylation, and thereby activates the PI3K/AKT/GSK3α pathway to promote ICC cell proliferation, migration, and invasion. |
Co-immunoprecipitation, immunofluorescence, western blot for pathway components, overexpression and knockdown, in vivo xenograft |
Oncology reports |
Medium |
40747713
|
| 2018 |
PRL-1 redistributes to the immunological synapse (IS) in two stages: first transiently at scanning membranes enriched in CD3 and actin, then delivered from pericentriolar CD3ζ-containing vesicles; at the established IS it distributes to LFA-1 and CD3ε sites. PRL-1 regulates actin dynamics during IS assembly and is required for IL-2 secretion; pharmacological inhibition of PRL catalytic activity reduces IL-2 secretion. |
Live imaging, immunofluorescence, pharmacological catalytic inhibition, siRNA knockdown, IL-2 secretion assay |
Frontiers in immunology |
Medium |
30515156
|
| 1999 |
The transcription factor Egr-1 binds a specific site in the proximal PRL-1 promoter P1 and is sufficient to transactivate PRL-1 gene expression; an intact Egr-1 binding site is required for PRL-1 upregulation in response to mitogen stimulation. |
EMSA, promoter reporter assays (luciferase), mutant Egr-1 binding site, Egr-1 binding activity in regenerating liver |
The Journal of biological chemistry |
Medium |
9988683
|
| 2022 |
PRL1 promotes glioblastoma invasion by stabilizing the EMT transcription factor Snail2 through activation of the deubiquitinase USP36; PRL1 expression activates USP36, which deubiquitinates and stabilizes Snail2, and knockdown of PRL1 blocks EMT, invasion, and tumor growth. |
Overexpression and knockdown, ubiquitination assays, Co-IP for PRL1-USP36-Snail2 interactions, in vivo xenograft |
Frontiers in oncology |
Medium |
35111679
|
| 2024 |
PTP4A1 oxidized form (disulfide-bonded between Cys104 and Cys49) retains a key biological function: it forms a kinase-phosphatase complex with Src kinases independently of phosphatase activity, as demonstrated in systemic sclerosis fibroblasts. |
Production of oxidized and reduced PTP4A1 recombinant protein, Co-IP/complex formation assay with Src |
Methods in molecular biology |
Low |
38147218
|